Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
企業コードGH
会社名Guardant Health Inc
上場日Oct 04, 2018
設立日2011
最高経営責任者「CEO」Dr. Amirali Talasaz, Ph.D.
従業員数1999
証券種類Ordinary Share
決算期末Oct 04
本社所在地3100 Hanover Street
都市PALO ALTO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94304
電話番号18556988887
ウェブサイトhttps://guardanthealth.com/
企業コードGH
上場日Oct 04, 2018
設立日2011
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし